Recent advances in understanding chemotherapy-induced peripheral neuropathy

F1000Res. 2020 Mar 11:9:F1000 Faculty Rev-177. doi: 10.12688/f1000research.21625.1. eCollection 2020.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.

Keywords: Chemotherapy; Neuropathy; Pain; Survivorship.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Humans
  • Neoplasms / drug therapy
  • Paclitaxel / adverse effects
  • Pain / chemically induced*
  • Peripheral Nervous System Diseases / chemically induced*
  • Quality of Life

Substances

  • Antineoplastic Agents
  • Paclitaxel

Grants and funding

The author(s) declared that no grants were involved in supporting this work.